Daily Respiratory Research Analysis
Analyzed 126 papers and selected 3 impactful papers.
Summary
Analyzed 126 papers and selected 3 impactful articles.
Selected Articles
1. Amikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial.
In newly diagnosed noncavitary MAC lung disease, adding ALIS to azithromycin and ethambutol increased and accelerated culture conversion versus an empty-liposome comparator and improved respiratory quality-of-life trends without new safety signals. A majority of converters on ALIS achieved first negative culture by month 1.
Impact: This double-blind RCT extends ALIS benefits beyond refractory disease, suggesting a potential shift in first-line regimens for selected newly diagnosed MAC lung disease patients.
Clinical Implications: Consider ALIS addition to macrolide–ethambutol backbones in newly diagnosed noncavitary MACLD to increase and expedite culture conversion, while monitoring patient-reported respiratory outcomes.
Key Findings
- By month 6, culture conversion occurred in 80.6% with ALIS vs 63.9% with comparator; by month 7, 78.8% vs 47.1% (nominal P=0.0010).
- Among converters by month 6, 74.3% in the ALIS arm achieved first negative culture at month 1 vs 46.7% in comparator.
- QOL-B RD improved over 7 months with ALIS, whereas comparator plateaued after month 3; PROMIS Fatigue improved in both groups without between-arm difference.
- No ALIS-related serious adverse events or deaths; no new safety signals.
Methodological Strengths
- Randomized, double-blind, active-comparator design with trial registration (NCT04677543).
- Assessment of both microbiological endpoints and validated patient-reported outcomes.
Limitations
- Modest sample size (n=99) and restricted to noncavitary MACLD, limiting generalizability.
- Nominal P values; not powered for long-term relapse or hard clinical outcomes.
Future Directions: Confirm findings in larger, diverse MACLD populations (including cavitary disease), assess durability of conversion, relapse rates, and impact on exacerbations and survival.
RATIONALE: Guidelines recommend amikacin liposome inhalation suspension (ALIS) for refractory Mycobacterium avium complex lung disease (MACLD) treatment, alongside other antibiotics. Efficacy of ALIS on microbiological endpoints and patient-reported outcomes (PROs) in the newly diagnosed MACLD population is unknown. OBJECTIVES: ARISE aimed to validate Quality of Life-Bronchiectasis Respiratory Domain (QOL-B RD) and Patient-Reported Outcomes Measurement Information System Short Form v1.0-Fatigue 7a (PROMIS F SF-7a) in patients treated for new/recurrent MACLD. We present treatment outcome results, including microbiological endpoints, PROs, and safety. METHODS: Adults with noncavitary MACLD were randomized 1:1 to ALIS (590 mg) or empty liposome control (comparator), plus azithromycin (250 mg) and ethambutol (15 mg/kg) once daily for 6 months, then 1 month off treatment. RESULTS: Of 99 patients, most had Mycobacterium intracellulare (43.4%) and/or M avium (32.3%) infections. Culture conversion with ALIS was achieved by 80.6% by month 6 (comparator, 63.9%) and 78.8% by month 7 (comparator, 47.1%; nominal P = .0010). Among patients achieving culture conversion by month 6, first negative culture defining conversion occurred at month 1 for 74.3% with ALIS (comparator, 46.7%). Mean QOL-B RD score through month 7 improved with ALIS versus plateauing with comparator after month 3; both arms showed improved PROMIS F SF-7a without between-arm difference. Positive correlations between culture conversion and improved QOL-B RD score were observed with ALIS. No ALIS-related serious adverse events or deaths were reported. CONCLUSIONS: More patients with newly diagnosed MACLD receiving 6 months of ALIS alongside a macrolide-based regimen achieved culture conversion by month 6 and month 7 numerically more rapidly versus comparator. No new safety signals were identified.Clinical trial registered with www.clinicaltrials.gov (NCT04677543).
2. The RNA-binding protein ALYREF promotes mitochondrial dysfunction and ferroptosis in CD4
Mechanistic study showing ALYREF and its target ZWINT are upregulated in COPD-associated NSCLC; ALYREF stabilizes ZWINT mRNA, driving mitochondrial dysfunction and ferroptosis in CD4+ T cells in murine and in vitro models, implicating an immunosuppressive axis in the tumor microenvironment.
Impact: Identifies a novel ALYREF–ZWINT molecular axis linking RNA regulation to CD4+ T-cell dysfunction and ferroptosis in COPD-associated NSCLC, offering a potential therapeutic or biomarker target in tumor immunology.
Clinical Implications: Provides a mechanistic rationale for targeting ALYREF–ZWINT-mediated pathways to restore CD4+ T-cell function in COPD-associated NSCLC; may inform development of immunomodulatory therapies or biomarkers for patient stratification.
Key Findings
- ALYREF and ZWINT expression are significantly upregulated in COPD-associated NSCLC tumors (reported from tumor samples in the study).
- ALYREF binds directly to ZWINT mRNA and increases its stability, leading to higher ZWINT protein expression.
- Upregulation of ALYREF–ZWINT drives mitochondrial dysfunction and ferroptosis in CD4+ T cells in murine and in vitro models.
Methodological Strengths
- Use of both in vivo (murine COPD-associated NSCLC model) and in vitro systems to validate mechanistic findings.
- Molecular evidence of direct ALYREF–ZWINT mRNA interaction and downstream functional assays linking to mitochondrial dysfunction and ferroptosis.
Limitations
- Abstract truncated in source; full data details, cohort/sample sizes, and statistical metrics are not available in the supplied text.
- Translational relevance to human patients requires validation in clinical samples and functional rescue experiments in human cells.
Future Directions: Validate ALYREF–ZWINT expression and functional impact in human NSCLC/COPD patient samples; test whether inhibiting ALYREF or modulating ferroptosis rescues CD4+ T-cell function and improves antitumor immunity.
BACKGROUND AND AIMS: Immune dysfunction in the tumor microenvironment contributes to the progression of non-small cell lung cancer (NSCLC) in patients with chronic obstructive pulmonary disease (COPD). This study aimed to elucidate the roles of the RNA-binding protein Aly/REF export factor (ALYREF) and its target, ZW10 interacting protein (ZWINT), in mediating CD4 METHODS: A murine model of COPD-associated NSCLC was established, and an in vitro system simulating the disease microenvironment was built. Primary CD4 RESULTS: ALYREF and ZWINT were significantly upregulated in COPD-associated NSCLC tumors. ALYREF directly bound to ZWINT mRNA, enhancing its stability and increasing its expression. This upregulation drove CD4 CONCLUSION: The ALYREF-ZWINT axis promotes CD4
3. [Dyspnoea in invasively ventilated patients: an overview].
Consensus-based overview highlighting under-recognized dyspnoea in invasively ventilated patients; emphasizes systematic assessment (including for non-communicative patients), links dyspnoea to lung- and diaphragm-protective ventilation strategies, and discusses targeted diagnostic and therapeutic options.
Impact: Provides a consolidated, society-endorsed synthesis of assessment and management strategies for dyspnoea during mechanical ventilation, which can standardize practice and improve patient-centered outcomes in ICU settings.
Clinical Implications: Encourages routine, systematic dyspnoea assessment in ventilated patients (including validated tools for non-communicative patients), integration of dyspnoea considerations into lung/diaphragm-protective ventilation and weaning protocols, and targeted interventions to address physiological and psychological contributors.
Key Findings
- Dyspnoea during invasive mechanical ventilation is common and often underestimated in clinical practice.
- ERS and ESICM consensus emphasizes validated, systematic assessment tools applicable to both communicative and non-communicative patients.
- Assessment of dyspnoea should inform lung- and diaphragm-protective ventilation strategies and weaning plans, with targeted diagnostic and therapeutic options available.
Methodological Strengths
- Based on a comprehensive ERS/ESICM consensus statement, providing expert-agreed recommendations.
- Addresses both physiological and psychological dimensions and includes guidance for non-communicative patients.
Limitations
- As an overview based on consensus, it does not provide new primary empirical data.
- Implementation barriers (resource-, training-related) for systematic dyspnoea assessment in some ICUs may limit immediate uptake.
Future Directions: Prospective studies to validate recommended assessment tools in diverse ICU populations, intervention trials assessing dyspnoea-directed management on clinical and patient-reported outcomes, and implementation research for integration into weaning and protective ventilation protocols.
Dyspnoea is a highly relevant phenomenon in patients undergoing invasive mechanical ventilation, yet it is often underestimated in clinical practice. Against this background, the European Respiratory Society (ERS) and the European Society of Intensive Care Medicine (ESICM) have published a comprehensive statement on the various aspects of dyspnoea during mechanical ventilation. This article is based on this consensus document and highlights the various dimensions of dyspnoea, from its prevalence and clinical relevance to the individual experiences of patients and its physiological and psychological consequences. It provides a detailed presentation of diagnostic procedures and targeted therapeutic intervention options. Particular emphasis is placed on systematic assessment tools offering valid evaluation approaches for both communicative and non-communicative patients. Additionally, the importance of dyspnoea in relation to lung- and diaphragm-protective ventilation and weaning from mechanical ventilation is discussed. Dyspnoe ist ein hochrelevantes Phänomen bei invasiv beatmeten Patientinnen, das in der klinischen Praxis jedoch häufig unterschätzt wird. Vor diesem Hintergrund haben die European Respiratory Society (ERS) und die European Society of Intensive Care Medicine (ESICM) eine umfassende Stellungnahme zu den unterschiedlichen Aspekten der Dyspnoe unter maschineller Beatmung herausgegeben. Der vorliegende Beitrag beleuchtet auf Basis dieses Konsensdokuments die verschiedenen Dimensionen der Dyspnoe: von der Prävalenz und der klinischen Relevanz bis hin zum individuellen Erleben der Patientinnen sowie den physiologischen und psychischen Konsequenzen. Im Fokus stehen dabei die fundierte Darstellung diagnostischer Verfahren sowie gezielte therapeutische Interventionsmöglichkeiten. Ein besonderer Schwerpunkt liegt auf systematischen Erfassungsinstrumenten, die sowohl für kommunikationsfähige als auch für nicht kommunikationsfähige Patient*innen valide Ansätze zur Einschätzung bieten. Darüber hinaus wird die Relevanz der Dyspnoe im Zusammenhang mit der lungen- und diaphragmaprotektiven Beatmung sowie dem Weaning von der invasiven Beatmung diskutiert.